Trial Profile
A randomised phase II trial to evaluate the efficacy of DPX-Survivac (EMD 640744) in patients with advanced ovarian cancer
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 24 Mar 2015
Price :
$35
*
At a glance
- Drugs Maveropepimut-S (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 20 Mar 2015 The design of this large randomised trial is being finalised and it is expected to be initiated in 2015, according to an Immunovaccine media release.
- 07 Jul 2014 New trial record